



Professor Celia Morgan

PHD, BSC, DIP SCICOMM
HEAD OF KETAMINE ASSISTED PSYCHOTHERAPY FOR
ADDICTION – AWAKN LIFE SCIENCES

Prof. Celia Morgan is Head of Ketamine-Assisted Psychotherapy for alcohol use disorder practice at Awakn Life Sciences, a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder.

Prof. Morgan completed her undergraduate degree and PhD at University College London (UCL) and completed a scholarship programme at Yale University. After working at University of Melbourne, Australia, as a visiting research fellow, she returned to UCL for Lectureship before joining University of Exeter as a Senior Lecturer in 2013; and was given a Chair in Psychopharmacology in 2015.

Prof. Morgan holds an Honorary Readership at University College London, is the academic lead for both Exeter Translational Addiction Partnership and is the head of psychology at the School of Psychology, Exeter.

Through behavioural, neuroimaging studies and clinical trials, Prof. Morgan has investigated the effects of ketamine and MDMA in combination with psychological therapies aimed at the treatment of addiction.

She carried out the ground-breaking Ketamine for reduction of Alcoholic Relapse (KARE) trial – a recent randomised controlled trial exploring combined use of psychological therapy and a low dose of ketamine as a possible treatment for alcoholism – the first of its kind.

Relevant publications

- Borissova, A., Ferguson, B., Morgan, C., et al (2020). **Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment.** Journal of Psychopharmacology
- Grabski M, Borissova A, Marsh B, Morgan CJA, Curran HV. (2020) **Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review.** Behav Brain Res. 2020 Aug 17;392:112629.
- Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA. (2018) **Ketamine for the treatment of addiction: Evidence and potential mechanisms.** Neuropharmacology. 2018
- McAndrew, A., Lawn, W., Stevens, TS, Porffy, L., Brandner, B, Morgan CJA (2017) **A Proof of Concept investigation of ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial** Trials 18:159
- Morgan CJA, Lawn, W, McAndrew A, Stevens, T, Nutt DJ (2017) **Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use.** Current Opinion in Behavioural Science 13: 71–76
- Singh IL Morgan CJA., Schlag A., Curran HV., Nutt DJ., McShane R, (2017) **Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight..** Lancet Psychiatry 4(5):419- 426